Liabilities / Assets
99th percentile
Higher debt load relative to assets than 99% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
6.53x
Liabilities / Revenue
99th percentile
Higher debt load relative to revenue than 99% of similar nonprofits.
Net Margin
1st percentile
Higher net margin than 1% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
2nd percentile
Faster asset growth than 2% of similar nonprofits.
Revenue Growth
9th percentile
Faster revenue growth than 9% of similar nonprofits.
Balance Sheet
Assets
Down$4,745
Down $60,390 (-93%) from 2022
Net Assets
-
No earlier filing loaded for comparison.
Liabilities
Flat$31,000
Flat from 2022
Revenue And Expenses
Revenue
Down$5,359
Down $6,776 (-56%) from 2022
Expenses
Up$65,749
Up $40,942 (+165%) from 2022
Net Income
Down-$60,390
Down $47,718 (-377%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
Cure first mission is to accelerate discovery of targeted and less toxic treatment for cancer using innovative technologies.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990EZSummary only. Only limited summary data is available for this year.
- Assets
- $4,745
- Liabilities
- $31,000
- Net assets
- -
- Revenue
- $5,359
- Expenses
- $65,749
- Net income
- -$60,390